Nucala 100 mg, Lyophilisat zur Herstellung einer Injektionslösung
7680657310016
CH-65731
Lyophilisat
Associated product:
Nucala 100 mg, Lyophilisat zur Herstellung einer Injektionslösung
1 / 3
google
Article details
- Package size
- 1
- Selling units
- 1
- Measure
- Durchstechflasche(n)
- Galenic form
- Lyophilisat
- Galenic group
- Lösbar zur Injektion/Infusion
Official Swissmedic V2 data
Additional information from the official database
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
PRC
|
100.0 MG | Substance | Wirkstoff (Principe actif) |
|
PRC
|
- | Substance | HNIDK |
|
PRC
|
- | Substance | HNIDK |
|
PRC
|
- | Substance | HBESI |
|
PRC
|
- | Substance | HNIDK |
Authorization holder
GlaxoSmithKline AG
6340 Baar
Authorization information
- Swissmedic authorization number
- 65731
- Drug name
- Nucala, Lyophilisat zur Herstellung einer Injektionslösung
- Galenic form
- PULVL
- ATC Code
- R03DX09
- Authorization status
- Revoked/Withdrawn
- Dispensing category
- B
- First authorization
- 07/04/2016
- Authorization expiration date
- 30/06/2025
- IT Number
- 03.04.5.
- Domain
- Human medicine
Package details
- Description (FR)
- NUCALA subst sèche 100 mg/ml flac
- Description (DE)
- NUCALA Trockensub 100 mg/ml Durchstf
- Market launch
- 07/04/2016
- Market withdrawal
- 24/06/2025
- Narcotic (BTM)
- No